2-(5-Methyl-1H-indol-3-yl)-acetamide | 91350-17-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-(5-Methyl-1H-indol-3-yl)-acetamide
• 英文别名: 2-(5-methyl-1H-indol-3-yl)acetamide
• CAS: 91350-17-3
• 化学式: C₁₁H₁₂N₂O
• mdl: MFCD00022755
• 分子量: 188.229
• InChiKey: VQXXRQMLQUGSQL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.181
• 拓扑面积：
  58.9
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (1-Methyl-1H-indol-7-yl)-oxo-acetic acid methyl ester 、 2-(5-Methyl-1H-indol-3-yl)-acetamide 生成 3-(5-Methyl-1H-indol-3-yl)-4-(1-methyl-1H-indol-7-yl)pyrrole-2,5-dione
  参考文献：
  名称：

  新型，有效和选择性的细胞周期蛋白D1 / CDK4抑制剂：吲哚[6,7-a]吡咯并[3,4-c]咔唑。

  摘要：

  报道了一系列吲哚[6，7-a]吡咯并[3，4-c]咔唑的合成和CDK抑制性能。这些化合物除了具有强大的CDK活性外，还具有针对两种人类癌细胞系的抗增殖活性。这些抑制剂还影响这些细胞系中的强G1阻滞，并抑制Ser780处的Rb磷酸化，这与抑制细胞周期蛋白D1 / CDK4一致。

  DOI：

  10.1016/s0960-894x(03)00461-x

文献信息

• PYRROLO[2,3-d]PYRIMIDINE TROPOMYSIN-RELATED KINASE INHIBITORS
  申请人：Andrews Mark David

  公开号：US20120258950A1

  公开（公告）日：2012-10-11

  The present invention relates to compounds of Formula (I) and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as Trk antagonists.

  本发明涉及式(I)化合物及其药学上可接受的盐，其中取代基如本文所述，并且它们在医学上的用途，特别是作为Trk拮抗剂。
• COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER
  申请人：ArQule, Inc.

  公开号：US20150328208A1

  公开（公告）日：2015-11-19

  The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

  本发明提供了治疗细胞增殖紊乱（如癌症）的方法，通过向需要的受试者投予一种吡啶喹啉基吡咯-2,5-二酮化合物或吡啶喹啉基吡咯啉-2,5-二酮化合物的治疗有效量，与第二种抗增殖剂的治疗有效量结合使用。
• [EN] COMBINATIONAL COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER<br/>[FR] COMPOSITIONS COMBINATOIRES ET PROCÉDÉS POUR LE TRAITEMENT DU CANCER
  申请人：ARQULE INC

  公开号：WO2010093789A2

  公开（公告）日：2010-08-19

  The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or a pyrroloquinolinyl-pyrrolidine-2,5-dione compound in combination with a therapeutically effective amount of a second anti-proliferative agent.

  本发明提供了一种治疗细胞增殖性疾病（如癌症）的方法，通过向需要治疗的受试者施用一种吡咯喹啉基-吡咯烷-2,5-二酮化合物或吡咯喹啉基-吡咯啉-2,5-二酮化合物的治疗有效量，与治疗有效量的第二种抗增殖剂联合使用。
• Novel pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
  申请人：Holder Swen

  公开号：US20050026918A1

  公开（公告）日：2005-02-03

  The present invention relates to novel pyridazinone derivatives of the general formula (I) wherein A is A1 or A2; R is unsubstituted or at least monosubstituted C 1 -C 10 -alkyl, aryl, aryl-(C 1 -C 10 -alkyl)-, heteroaryl, heteroaryl-(C 1 -C 10 -alkyl)-, heterocyclyl, heterocyclyl-(C 1 -C 10 -alkyl)-, C 3 -C 10 -cycloalkyl, polycycloalkyl, C 2 -C 10 -alkenyl or C 2 -C 10 -alkinyl and Ar is unsubstituted or at least monosubstituted aryl or heteroaryl.

  本发明涉及一种新型吡啶并咪唑酮衍生物，其通式为(I)，其中A为A1或A2；R为未取代或至少单取代的C1-C10烷基、芳基、芳基-(C1-C10烷基)-、杂芳基、杂芳基-(C1-C10烷基)-、杂环基、杂环基-(C1-C10烷基)-、C3-C10环烷基、多环环烷基、C2-C10烯基或C2-C10炔基，Ar为未取代或至少单取代的芳基或杂芳基。
• Compositions and methods for treatment of cancer
  申请人：Li J. Chiang

  公开号：US20060223760A1

  公开（公告）日：2006-10-05

  The present invention relates to pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds, and methods of preparation of these compounds. The present invention also relates to pharmaceutical compositions comprising pyrroloquinolinyl-pyrrole-2,5-dione compounds and pyrroloquinolinyl-pyrrolidine-2,5-dione compounds. The present invention provides methods of treating a cell proliferative disorder, such as a cancer, by administering to a subject in need thereof a therapeutically effective amount of a pyrroloquinolinyl-pyrrole-2,5-dione compound or pyrroloquinolinyl-pyrrolidine-2,5-dione compound of the present invention.

  本发明涉及吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯啉-2,5-二酮化合物，以及这些化合物的制备方法。本发明还涉及包含吡咯喹啉基吡咯-2,5-二酮化合物和吡咯喹啉基吡咯啉-2,5-二酮化合物的药物组合物。本发明提供了通过向需要治疗细胞增殖性疾病，如癌症的患者投与本发明的吡咯喹啉基吡咯-2,5-二酮化合物或吡咯喹啉基吡咯啉-2,5-二酮化合物的治疗有效量的方法。